Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 9:24 PM ET


Company Overview of Vivaldi Biosciences, Inc.

Company Overview

Vivaldi Biosciences, Inc., a biotechnology company, develops vaccines for the prevention of common seasonal influenza and emergent pandemic flu. It focuses on developing live attenuated influenza vaccines by altering the gene for nonstructural protein 1 (NS1), a key virulence factor of influenza, and other negative-strand RNA viruses. The company was founded in 2006 and is based in New York, New York.

3185-A Rampart Road

Research Innovation Center

Fort Collins, CO 80523-0922

United States

Founded in 2006


970 492 4365

Key Executives for Vivaldi Biosciences, Inc.

Chairman, Chief Executive Officer and President
Age: 63
Co-Founder and Chairman of Scientific Advisory Board
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Member of Scientific Advisory Board
Chief Financial Officer
Compensation as of Fiscal Year 2015.

Vivaldi Biosciences, Inc. Key Developments

Vivaldi Biosciences, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014

Vivaldi Biosciences, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.

Vivaldi Biosciences Inc. Signs Cooperative Research and Development Agreement with National Institute of Allergy and Infectious Diseases

Vivaldi Biosciences Inc. announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9). The H7N9 strain is of concern due to its pandemic potential. Human cases of this avian-origin influenza strain were first recognized in early 2013. Vivaldi's LAIV technology platform uses the biology of the influenza nonstructural protein 1 (NS1) to provide a new vaccine approach with the potential for superior efficacy and protection. NS1 is a multifunctional virulence factor of the influenza virus. Vivaldi uses proprietary reverse genetics and plasmid rescue technologies to modify the NS1 gene, generating replication-deficient LAIVs attenuated for safety and able to produce a potent, protective immune response. Research under the CRADA will use Vivaldi's LAIV master strain, which incorporates a specifically truncated NS1 gene and other attenuating genes. The Vivaldi and NIAID teams jointly will select, clone and manipulate H7N9 genes for insertion into Vivaldi's master strain to generate candidate LAIVs against influenza H7N9. Vivaldi and NIAID together will conduct in vitro and in vivo evaluations of the candidate LAIVs, including studies of safety, immunogenicity and protective efficacy in animal models, and will carry out Good Laboratory Practices (GLP) toxicology evaluations of the candidate LAIVs. Data generated in the program are expected to support the filing of an Investigational New Drug (IND) application for a Phase 1 clinical trial in volunteers.

Similar Private Companies By Industry

Company Name Region
APE-BridgePath Scientific, LLC United States
HumanZyme, Inc. United States
N-of-One, Inc. United States
Axerion Therapeutics, Inc. United States
Mergen Ltd. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Vivaldi Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at